Baricitinib versus placebo or adalimumab in rheumatoid arthritis

Baricitinib versus placebo or adalimumab in rheumatoid arthritis

<h4>Background</h4> <p>Baricitinib is an oral, reversible, JAK1/JAK2 inhibitor that may have therapeutic value in patients with rheumatoid arthritis.</p> <h4>Methods</h4> <p>In this 52-week, phase 3, double-blind, placebo and active-controlled study, 1307 p...

Bibliografske podrobnosti
Main Authors:	Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y
Format:	Journal article
Izdano:	Massachusetts Medical Society 2017

Podobne knjige/članki

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM
od: Taylor, P, et al.
Izdano: (2016)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
od: Keystone, E, et al.
Izdano: (2017)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
od: Taylor, P, et al.
Izdano: (2017)

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
od: Emery, P, et al.
Izdano: (2017)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2017)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
od: Weinblatt, M, et al.
Izdano: (2018)

Improved patient-reported outcomes in patients with rheumatoid arthritis who failed adalimumab or placebo treatment and were rescued with baricitinib
od: Fautrel, B, et al.
Izdano: (2017)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
od: Tanaka, Y, et al.
Izdano: (2019)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
od: Keystone, EC, et al.
Izdano: (2017)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
od: Keystone, E, et al.
Izdano: (2015)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
od: Paul Emery, et al.
Izdano: (2020-05-01)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
od: Tanaka, Y, et al.
Izdano: (2018)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
od: Weinblatt, M, et al.
Izdano: (2017)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
od: Paul Emery, et al.
Izdano: (2020-07-01)

Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase 2b study in patients with active rheumatoid arthritis
od: Kremer, J, et al.
Izdano: (2017)

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2019)

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2021)

Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM
od: Fautrel, B, et al.
Izdano: (2019)

Efficacy and safety of baricitinib versus placebo and adalimumab in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate: Summary results from the 52-week phase 3 RA-beam study
od: Taylor, P, et al.
Izdano: (2017)

Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis
od: Peterfy, C, et al.
Izdano: (2019)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
od: Schlueter M, et al.
Izdano: (2019-06-01)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
od: Weinblatt, M, et al.
Izdano: (2018)

24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
od: Taylor, P, et al.
Izdano: (2013)

Baricitinib for the treatment of rheumatoid arthritis
od: Ivan Urits, et al.
Izdano: (2020-12-01)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
od: Taylor, P, et al.
Izdano: (2019)

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
od: Genovese, M, et al.
Izdano: (2012)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
od: Taylor, P, et al.
Izdano: (2019)

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
od: Tanaka, Y, et al.
Izdano: (2021)

Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.
od: Peterfy, C, et al.
Izdano: (2012)

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
od: Désirée van der Heijde, et al.
Izdano: (2019-06-01)

Comparative effectiveness in pain and haq-di improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naÏve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC)
od: Fautrel, B, et al.
Izdano: (2018)

Cost per number needed to treat and treatment cost of baricitinib versus adalimumab on rheumatoid arthritis treatment in the brazilian private healthcare system
od: Bruno Corona Prandi, et al.
Izdano: (2023-02-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
od: Smolen, JS, et al.
Izdano: (2024)

Baricitinib exposure during pregnancy in rheumatoid arthritis
od: Giulia Costanzo, et al.
Izdano: (2020-01-01)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
od: Taylor, P, et al.
Izdano: (2018)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
od: Taylor, PC, et al.
Izdano: (2023)

Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies
od: Taylor, PC, et al.
Izdano: (2023)

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
od: Peter C. Taylor, et al.
Izdano: (2023-01-01)

Cutaneous eruption after commencing baricitinib for rheumatoid arthritis
od: Rosemary Akinbisehin, et al.
Izdano: (2024-06-01)